Health-care system plans to acquire Dulles-based IBA Molecular North America

Published April 17, 2015 by Veronica Garabelli

Illinois Health and Science (IHS), a health-care system based in Decatur, Ill., plans to acquire IBA Molecular North America (IBAM NA) in Dulles, the companies said Friday. Terms of the deal were not disclosed.

IBAM NA, which makes and distributes radiopharmaceuticals, will continue to operate as an independent company and remain based in Dulles. IBAM NA is the U.S. operation of IBA Molecular.

IHS is the parent company of Decatur Memorial Hospital, a hospital with more than $900 million in revenues, and Zevacor Molecular Inc., which is developing a new, high-capacity radiopharmaceutical production facility near Indianapolis. IBAM NA will work with Zevacor to produce a wide range of radionuclides for research and clinical applications.

“The acquisition of IBAM NA is highly complementary to the IHS investment in the radiopharmaceutical and molecular imaging industry and is a logical and important part of our strategic plan to be a leader in providing state-of-the-art health care,” Ken Smithmier, the CEO of IHS, Decatur Memorial Hospital and Zevacor, said in a statement.